POST – COVID SYNDROME. REVIEW
Introduction: Coronaviruses are important pathogens of humans and animals. At the end of 2019, a new coronavirus was identified as the cause of a group of pneumonia cases in Wuhan, a city in the Chinese province of Hubei. It spread rapidly, leading to an epidemic throughout China, followed by a global pandemic. Objective: to analyze and systematize publications devoted to the study of clinical and laboratory markers of post-COVID syndrome. Search strategy: literature search was carried out in the electronic databases PubMed, The Cochrane library, Google Scholar and e-library by keywords (COVID-19, markers of post-COVID syndrome, variants of SARS-CoV-2, long-term manifestations of COVID-19, post-COVID complications). Relevant papers reflecting the characteristics of the problem were accepted for description in the review. Results: Long-term manifestations of COVID-19 include lesions from the respiratory, cardiovascular, renal, endocrine, reproductive, central nervous system, gastrointestinal tract and liver, as well as inflammatory, autoimmune and rheumatological complications, chronic pain, chronic fatigue. Psychiatric/emotional health and well-being suffers, which leads to a deterioration in the quality of life of patients. Conclusions: It is extremely important to determine which patients are at risk and which will require long-term follow-up. There is a great need for strategies regarding screening processes, resource provision, approved care pathways, and multidisciplinary rehabilitation services.
COVID-19, markers of post-COVID syndrome, variants of SARS-CoV-2, long-term manifestations of COVID-19, post-COVID complications.
1. Alharthy A. [et al.]. Residual Lung Injury in Patients Recovering From COVID-19 Critical Illness // Journal of Ultrasound in Medicine. 2021. № 9 (40). C. 1823–1838. 2. Apicella M. [et al.]. COVID-19 in people with diabetes: understanding the reasons for worse outcomes // The Lancet Diabetes & Endocrinology. 2020. № 9 (8). C. 782–792. 3. Arnold D.T. [et al.]. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort // Thorax. 2021. № 4 (76). C. 399–401. 4. Ayoubkhani D. [et al.]. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study // BMJ. 2021. (372). 5. Bandyopadhyay D. [et al.]. COVID-19 Pandemic: Cardiovascular Complications and Future Implications // American Journal of Cardiovascular Drugs. 2020. № 4 (20). C. 311–324. 6. Boika A.V. A Post-COVID-19 Parkinsonism in the Future? // Movement Disorders. 2020. № 7 (35). C. 1094–1094. 7. Brancatella A. [et al.]. Subacute Thyroiditis After Sars-COV-2 Infection // The Journal of Clinical Endocrinology & Metabolism. 2020. № 7 (105). C. 2367–2370. 8. Cares-Marambio K. [et al.]. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis // Chronic Respiratory Disease. 2021. (18). C. 1–12. 9. Carfì A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19 // JAMA - Journal of the American Medical Association. 2020. № 6 (324). C. 603–605. 10. Carvalho-Schneider C. [et al.]. Follow-up of adults with noncritical COVID-19 two months after symptom onset // Clinical Microbiology and Infection. 2021. № 2 (27). C. 258–263. 11. Chaná-Cuevas P. [et al.]. The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson’s Disease // Frontiers in Neurology. 2020. (11). C. 1044. 12. Chen X. [et al.]. A systematic review of neurological symptoms and complications of COVID-19 // Journal of Neurology. 2021. № 2 (268). C. 392–402. 13. Chopra V. [et al.]. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 // https://doi.org/10.7326/M20-5661. 2020. № 4 (174). C. 576–578. 14. Cohen M.E. [et al.]. A case of probable Parkinson’s disease after SARS-CoV-2 infection // The Lancet Neurology. 2020. № 10 (19). C. 804–805. 15. Crameri G.A.G. [et al.]. Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020 // Eurosurveillance. 2020. № 36 (25). C. 2001542. 16. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease // Nature Reviews Immunology 2011 11:2. 2011. № 2 (11). C. 98–107. 17. Ellul M.A. [et al.]. Neurological associations of COVID-19 // The Lancet Neurology. 2020. № 9 (19). C. 767–783. 18. Fang Y. [et al.]. Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: Preliminary experience // The American Journal of Emergency Medicine. 2020. № 10 (38). C. 2134–2138. 19. Frija-Masson J. [et al.]. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection // European Respiratory Journal. 2020. № 2 (56). 20. Garrigues E. [et al.]. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19 // Journal of Infection. 2020. № 6 (81). C. e4–e6. 21. Gorbalenya A.E. [et al.]. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nature microbiology. 2020. № 4 (5). C. 536–544. 22. Gutierrez Amezcua J.M. [et al.]. COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms // SN Comprehensive Clinical Medicine. 2020. № 11 (2). C. 2109–2125. 23. Halpin S.J. [et al.]. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation // Journal of Medical Virology. 2021. № 2 (93). C. 1013–1022. 24. Hascup E.R., Hascup K.N. Does SARS-CoV-2 infection cause chronic neurological complications? // GeroScience 2020 42:4. 2020. № 4 (42). C. 1083–1087. 25. Hoffmann M. [et al.]. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor // Cell. 2020. № 2 (181). C. 271-280.e8. 26. Huang C. [et al.]. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study // The Lancet. 2021. № 10270 (397). C. 220–232. 27. Huang L. [et al.]. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging // JACC: Cardiovascular Imaging. 2020. № 11 (13). C. 2330–2339. 28. Huang W. [et al.]. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19 // Journal of Infection. 2021. № 2 (82). C. e5–e7. 29. Iwashyna T.J. [et al.]. Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis // JAMA. 2010. № 16 (304). C. 1787–1794. 30. Johansson M. [et al.]. Long-Haul Post–COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience // JACC: Case Reports. 2021. № 4 (3). C. 573–580. 31. Kosugi E.M. [et al.]. Incomplete and late recovery of sudden olfactory dysfunction in COVID-19 // Brazilian Journal of Otorhinolaryngology. 2020. № 4 (86). C. 490–496. 32. Lau S.K.P. [et al.]. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment // Journal of General Virology. 2013. № PART 12 (94). C. 2679–2690. 33. Leung T.Y.M. [et al.]. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review // Emerging Microbes and Infections. 2020. № 1 (9). C. 2190–2199. 34. Lu Y. [et al.]. Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study: A brief title: Cerebral Changes in COVID-19 // EClinicalMedicine. 2020. (25). C. 100484. 35. Major J. [et al.]. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection // Science. 2020. № 6504 (369). C. 712–717. 36. Mateu-Salat M., Urgell E., Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19 // Journal of Endocrinological Investigation 2020 43:10. 2020. № 10 (43). C. 1527–1528. 37. Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: looking beyond the short term // Alzheimer’s Research & Therapy 2020 12:1. 2020. № 1 (12). C. 1–16. 38. Moreno-Pérez O. [et al.]. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study // Journal of Infection. 2021. № 3 (82). C. 378–383. 39. Ng M.Y. [et al.]. Patients Recovered From COVID-19 Show Ongoing Subclinical Myocarditis as Revealed by Cardiac Magnetic Resonance Imaging // JACC: Cardiovascular Imaging. 2020. № 11 (13). C. 2476–2478. 40. Nguyen Y. [et al.]. Virus detection and semiquantitation in explanted heart tissues of idiopathic dilated cardiomyopathy adult patients by use of PCR coupled with mass spectrometry analysis // Journal of Clinical Microbiology. 2013. № 7 (51). C. 2288–2294. 41. Ojo A.S. [et al.]. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies // Pulmonary Medicine. 2020. (2020). 42. Pan F. [et al.]. Time course of lung changes at chest CT during recovery from Coronavirus disease 2019 (COVID-19) // Radiology. 2020. № 3 (295). C. 715–721. 43. Paterson R.W. [et al.]. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings // Brain. 2020. № 10 (143). C. 3104–3120. 44. Pizzini A. [et al.]. Impact of Vitamin D Deficiency on COVID-19—A Prospective Analysis from the CovILD Registry // Nutrients 2020, Vol. 12, Page 2775. 2020. № 9 (12). C. 2775. 45. Puntmann V.O. [et al.]. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) // JAMA Cardiology. 2020. № 11 (5). C. 1265–1273. 46. Rajpal S. [et al.]. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection // JAMA Cardiology. 2021. № 1 (6). C. 116–118. 47. Raman B. [et al.]. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge // EClinicalMedicine. 2021. (31). C. 100683. 48. Rathore F.A., Ilyas A. Post-Intensive Care Syndrome and COVID-19: Crisis After a Crisis? // Heart, Lung and Circulation. 2020. № 12 (29). C. 1893–1894. 49. Richardson S. [et al.]. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area // JAMA. 2020. № 20 (323). C. 2052–2059. 50. Rosales-Castillo A., García de los Ríos C., Mediavilla García J.D. Persistencia de manifestaciones clínicas tras la infección COVID-19: importancia del seguimiento // Medicina Clínica. 2021. № 1 (156). C. 35–36. 51. Saloner B. [et al.]. Persistent Symptoms in Patients After Acute COVID-19 // JAMA. 2020. № 6 (324). C. 603–605. 52. Salvio G. [et al.]. Bone Metabolism in SARS-CoV-2 Disease: Possible Osteoimmunology and Gender Implications // Clinical Reviews in Bone and Mineral Metabolism. 2020. № 4 (18). C. 51–57. 53. Sardari A. [et al.]. Myocarditis detected after COVID-19 recovery // European Heart Journal - Cardiovascular Imaging. 2021. № 1 (22). C. 131–132. 54. Sasannejad C., Ely E.W., Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: A review of clinical impact and pathophysiological mechanisms // Critical Care. 2019. № 1 (23). C. 1–12. 55. Schwensen H.F. [et al.]. Fatal pulmonary fibrosis: a post-COVID-19 autopsy case // Journal of Clinical Pathology. 2021. № 6 (74). C. 400–402. 56. Shah A.S. [et al.]. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations // Thorax. 2021. № 4 (76). C. 402–404. 57. Sudre C.H. [et al.]. Attributes and predictors of long COVID // Nature medicine. 2021. № 4 (27). C. 626–631. 58. Troyer E.A., Kohn J.N., Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms // Brain, Behavior, and Immunity. 2020. (87). C. 34–39. 59. Valent A. [et al.]. Three-month quality of life in survivors of ARDS due to COVID-19: A preliminary report from a French academic centre // Anaesthesia Critical Care & Pain Medicine. 2020. № 6 (39). C. 740–741. 60. Wei J. [et al.]. WITHDRAWN: Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge // Clinical Imaging. 2020. 61. Wong C.K. [et al.]. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome // Clinical and Experimental Immunology. 2004. № 1 (136). C. 95–103. 62. Wu Y. [et al.]. Nervous system damage after COVID-19 infection: Presence or absence? // Brain, Behavior, and Immunity. 2020. (87). C. 55. 63. Xiong Q. [et al.]. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study // Clinical Microbiology and Infection. 2021. № 1 (27). C. 89–95. 64. Xu J. [et al.]. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis // Respiratory Research. 2020. № 1 (21). C. 1–12. 65. You J. [et al.]. Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge // Journal of Infection. 2020. № 2 (81). C. e150–e152. 66. Yu M. [et al.]. Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia // Korean Journal of Radiology. 2020. № 6 (21). C. 746–755. 67. Zhang C. [et al.]. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19 // Journal of Medical Virology. 2021. № 3 (93). C. 1378–1386. 68. Zhao Y. miao [et al.]. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery // EClinicalMedicine. 2020. (25). C. 100463. 69. Zhou P. [et al.]. A pneumonia outbreak associated with a new coronavirus of probable bat origin // Nature. 2020. № 7798 (579). C. 270–273. 70. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. 71. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18. PMID: 33555768. 72. Post-COVID Syndrome: What Should You Do If You Have Lingering COVID-19 Symptoms? | Houston Methodist On Health. https://www.houstonmethodist.org/global/why-choose-houston-methodist/blog/2020/nov/post-covid-syndrome-what-should-you-do-if-you-have-lingering-covid-19-symptoms/ 73. World Health Organization. Emergency use ICD codes for COVID-19 disease outbreak. Available from: https://www.who.int/classifications/icd/covid19/en/. Accessed March 28, 2020. 74. ICD 10 - 10th revision of the International Classification of Diseases. https://www.cdc.gov/nchs/icd/icd10.htm.
Количество просмотров: 242

Ключевые слова:

Библиографическая ссылка

Zhumanbayeva Zh.M., Кrykpaeva A.S., Serikbayev A.S., Dosbayeva А.М., Amrenova K.Sh., Sharapiyeva A.М., Kudaibergenov R.N., Juszkiewicz K., Zhussupov S.M. Post–COVID syndrome. Review // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 5, pp. 45-51. doi 10.34689/SH.2022.24.5.006

Авторизируйтесь для отправки комментариев